Table 1.
Patient characteristics in our cohort
| Characteristic | No. (%) |
|---|---|
| Age (yr) | |
| Median (range) | |
| ≤ 47 | 114 (50.4) |
| > 47 | 112 (49.6) |
| Sex | |
| Male | 188 (83.2) |
| Female | 38 (16.8) |
| No. of metastatic lesions | |
| ≤ 3 | 132 (58.4) |
| > 3 | 94 (41.6) |
| T categorya) | |
| T1 | 11 (4.9) |
| T2 | 31 (13.7) |
| T3 | 111 (49.1) |
| T4 | 73 (32.3) |
| N categorya) | |
| N0 | 7 (3.1) |
| N1 | 42 (18.6) |
| N2 | 97 (42.9) |
| N3 | 80 (35.4) |
| PCT regimen | |
| TPF | 64 (28.3) |
| TP | 60 (26.5) |
| PF | 56 (24.8) |
| Other regimens | 46 (20.4) |
| Pre-EBV DNA (copy/mL) | |
| < 25,000 | 113 (50.0) |
| ≥ 25,000 | 113 (50.0) |
| EBV DNA after PCT | |
| Undetectableb) | 128 (56.6) |
| Detectableb) | 98 (43.4) |
| LRRT | |
| Yes | 157 (69.5) |
| No | 69 (30.5) |
| MRT | |
| Yes | 68 (30.1) |
| No | 158 (69.9) |
PCT, palliative chemotherapy; EBV, Epstein-Barr virus; TPF, cisplatin plus docetaxel plus 5-fluorouracil; TP, cisplatin plus docetaxel; PF, cisplatin plus 5-fluorouracil; LRRT, locoregional radiotherapy; MRT, metastasis radiotherapy.
a)
According to the 7th edition of the Union for International Cancer Control/American Joint Committee on Cancer staging system,
b)
Undetectable/detectable EBV DNA levels after neoadjuvant chemotherapy are based on a cut-off value of 0 copy/mL.